- Report
- June 2020
- 753 Pages
Global
From €3190EUR$3,300USD£2,740GBP
- Report
- May 2023
- 73 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- October 2022
- 94 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- August 2022
- 70 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Report
- August 2022
- 68 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Drug Pipelines
- April 2020
- 82 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Drug Pipelines
- April 2020
- 76 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Drug Pipelines
- November 2019
- 77 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
Alitretinoin is a drug used in the treatment of oncology diseases. It is a retinoid, a type of vitamin A derivative, and is used to treat cutaneous T-cell lymphoma (CTCL). Alitretinoin is the only approved systemic treatment for CTCL and is used to treat the skin lesions associated with the disease. It is also used to treat other types of cancer, such as acute promyelocytic leukemia. Alitretinoin is available in both oral and topical forms.
Alitretinoin is a relatively new drug, having been approved by the US Food and Drug Administration in 2000. It is used to treat a variety of cancers, including CTCL, and is generally well-tolerated. The drug has been shown to be effective in treating CTCL, with some patients experiencing complete remission.
Some companies in the alitretinoin market include GlaxoSmithKline, Novartis, and Sun Pharmaceuticals. Other companies involved in the development and manufacture of alitretinoin include Actavis, Teva Pharmaceuticals, and Mylan. Show Less Read more
